Viking Therapeutics begins exploratory oral maintenance dosing study of VK2735

Viking Therapeutics has begun an exploratory oral maintenance dosing study of VK2735, its dual agonist of GLP-1 and GIP receptors.

Detected & updated continuously · Source: Nebula